Labetalol (hydrochloride)

Labetalol (AH5158) hydrochloride is an orally available, selective α1-adrenergic recepto and non-selective β-adrenergic receptor competitive antagonist. Labetalol hydrochloride is an antihypertensive molecule that partially crosses the blood-brain barrier and has little effect on cardiac output. Labetalol hydrochloride can be used in the study of cardiovascular diseases, such as hypertension during pregnancy[1][2][3].

Product Specifications

CAS Number

[32780-64-6]

Product Name Alternative

AH-5158 hydrochloride; Sch-15719W

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Endocrinology; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Labetalol-hydrochloride.html

Purity

99.96

Solubility

DMSO : ≥ 100 mg/mL|H2O : 20 mg/mL (ultrasonic)

Smiles

O=C(N)C1=CC(C(O)CNC(C)CCC2=CC=CC=C2)=CC=C1O.[H]Cl

Molecular Formula

C19H25ClN2O3

Molecular Weight

364.87

Precautions

H302, H315, H319, H335

References & Citations

[1]Greenslade FC, et al. Labetalol binding to specific alpha- and beta-adrenergic sites in vitro and its antagonism of adrenergic responses in vivo. J Mol Cell Cardiol. 1979 Aug;11 (8) :803-11.|[2]Erdtsieck-Ernste EB, et al. Changes in adrenoceptors and monoamine metabolism in neonatal and adult rat brain after postnatal exposure to the antihypertensive labetalol. Br J Pharmacol. 1992 Jan;105 (1) :37-44.|[3]Johnson JD, et al. Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. Neuroscience. 2005;135 (4) :1295-307.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture and light)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Int J Clin Pract. 2021 Oct;75 (10) :e14509.|J Med Chem. 2021 Mar 11;64 (5) :2725-2738.|J Pharm Biomed Anal. 2021 Feb 20:195:113870.|Microchem J. 2025 Nov 24;220:116331.|Eur J Pharmacol. 2023 Feb 15:941:175499.